IL11 and Thrombocytopenia: IL-11, the only drug for CIT which is approved by the Food and Drug Administration in the United States, can elevate nadir of platelet count from 40×103/μL to 60×103/μL, while rhTPOs have been reported to elevate nadir (from 20×103/μL to 44×103/μL) and shorten the duration of thrombocytopenia [11, 29, 30].